<DOC>
	<DOC>NCT01451164</DOC>
	<brief_summary>To investigate the efficacy and safety of OPC-34712 in comparison with placebo in patients with schizophrenia.</brief_summary>
	<brief_title>A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Patients age 18 years or older to less than 65 years (at time of informed consent) diagnosed with schizophrenia based on DSMIVTR diagnostic criteria Patients who are hospitalized, or judged to required hospitalization, for acute relapse of schizophrenia at time of informed consent Patients who are experiencing acute exacerbation of psychotic symptoms Female patients who are breastfeeding or who have a positive pregnancy test (urine) result prior to receiving investigational medicinal product Patients presenting a first episode of schizophrenia based on the clinical judgment of the investigator Patients who are diagnosed with a disease other than schizophrenia (schizoaffective disorder, major depressive disorder, bipolar disorder, posttraumatic stress disorder, anxiety disorder, delirium, dementia, amnesia, or other cognitive disorder) based on current DSMIVTR Axis Î™ criteria, or who are diagnosed with a personality disorder (borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>